LONDON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- The translational regenerative medicine market has been undergoing considerable changes over the last few years. There are a number of therapies that have been launched into the market over the last few years. Stem cell therapies are being developed constantly and these are targeted at various indications, from the more common cardiovascular conditions to rarer orphan indications.
The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new Visiongain report you find 316-page report you will receive 107 tables and 66 figures– all unavailable elsewhere.
The 316-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Download your free report sample pages here: https://www.visiongain.com/Report/1843/Global-Translational-Regenerative-Medicine-Market-Prospects-2017-2027
Translational Regenerative Medicine regional market forecasts from 2017-2027, covering:
- United States
- Europe
- Asia-Pacific
- Rest of the World
• Global Translational Regenerative Medicine submarket forecasts from 2017-2027 covering:
- Stem Cell Therapies
- Tissue Engineered Products
- Gene Therapies
• Forecasts from 2017-2027 of the leading products in the Global Translational Regenerative Medicine market:
- Osteocel Plus
- Trinity ELITE
- TEMCELL /Prochymal
- Apligraf
- Dermagraft
- Epifix
- ReCell
- Neovasculgen
- Glybera (alipogene tiparvovec)
- IMLYGIC (talimogene laherparepvec)
See the report full table of contents here:
• Assessment of the leading companies in the Global Translational Regenerative Medicine market:
- Alphatec Spine
- Anterogen
- Athersys
- Avita Medical
- AxoGen
- Medipost
- Mesoblast
- NuVasive
- Ocata Therapeutics
- Organogenesis
- Osiris Therapeutics
- Pharmicell
- Regenerys
- TiGenix
- UniQure
- Vericel Corporation
• SWOT and Porter’s Five Force analysis of the translational regenerative medicine market
Visiongain’s study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.
Buy our report today Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.
Request your free report overview today. Please email Sara Peerun on sara.peerun@visiongain.com or call me on +44 (0) 207549 9987.
Companies Listed
Advanced BioHealing
Advanced Tissue Sciences
Advantagene
AlloSource
AlphaTec Spine
Amedica
Amgen
Amorcyte
Amorepacific Group
AnGes MG
Angioblast Systems
Anika Therapeutics
Anterogen
Apceth
Arcarios B.V
Ark Therapeutics
Athersys Inc
Avita Medical
AxoGen
Baxter
Beike Biotechnology
Benda Pharmaceutical
BioD
Bioheart
BioMed Realty Trust, Inc
BioSante Pharmaceuticals
BioTime
BioTissue AG
BioVex Inc
Blackstone Medical
BrainStorm Cell Therapeutics
Caladrius Biosciences
California Stem Cell Inc
Capricor
Cardio3BioSciences
Celgene
Cell Targeting
CellCo Tec
Cellerant Therapeutics
Cephalon
Ceregene
CHA Biotech
Chiesi Farmaceutici
Cipla
Co.don AG
Cold Genesys
Cook Biotech Inc
Cytomedix
Cytori Therapeutics
Daiichi Sankyo
DePuy Mitek (Johnson & Johnson)
FibroCell Science
Gamida Cell Ltd
Genzyme Corporation (Sanofi)
Histogenics
Humacyte
Human Stem Cell Institute
Insulete Inc
Interxon Corporation
ISTO Technologies
Janssen Biotech Inc
Japan Tissue Engineering Co
JCR Pharmaceuticals
Johnson & Johnson
Kinetic Concept Inc
LecTec Corporation
Lincoln Park Capital
Lonza
MacroCure
Medipost
Medtronic
Mesoblast
Mitsubishi Tanabe
Myriad Genetics
Neostem
Neuralstem
Nippon Zoki Pharmaceuticals
NuVasive
Ocata Therapeutics
OncoCyte
Organovo
Orphan Biovitrum AB (Sobi)
Orthofix
Orteq Ltd.
Osiris Therapeutics
Oxford BioMedica
Parcell Laboratories
Pfizer
Pharmicell
Regenerys
Reliance Life Sciences
ReNeuron
RTI Surgical
Rusnano Corporation
Sangamo Biosciences
Sanofi
Shanghai Sunway Biotech
Shenzhen Sibiono GeneTech
Shire
Singapore General Hospital
Skye Orthobiologics
Smith & Nephewbv
Sobi Partners
Spark Therapeutics
StemCells Inc.
Stempeutics Research
Stratatech Corporation
TCA Cellular Therapy
Tengion Inc
Teva Pharmaceuticals
TiGenix
UniQure
U.S. Stem Cell Inc.
Vericel Corporation
Viacyte Inc
Vital Therapies
WKD Holding Oy
Xcellerex
Xenetic Biosciences
Zimmer